Administration and Data Analytic Core

HARP ADA项目总结 在NIAAA资助的关于艾滋病毒和酒精的大型协调研究项目的20年经验基础上， 退伍军人老龄化队列研究(Vacs)和我们的大家庭，特征良好，全国性 退伍军人医疗管理局(VA)队列(VACO家庭)为这项研究提供了前所未有的资源 在有和没有感染艾滋病毒的老年人中饮酒的比例。源自电子健康记录(EHR)， 并经过严格的数据清理和表型验证，VACO系列共享通用数据 要素，包括20年来关于酒精和健康结果的纵向数据；它还包括行为 相似的未感染个体，使我们能够表征艾滋病毒感染在确定酒精含量方面的作用 并支持有针对性的转化性和干预性研究。以支持优秀的 解决问题、研究设计和分析，我们已经建立了一个国际合作网络 专家。这些完善的基础设施带来了卓越的生产力。我们的调查人员已经 使用VACO系列的数据制作了500种同行评议的出版物，被引用26,000次(h指数79次)。 我们成功地协调了关于酒精在脑内的作用的观察性和干预性研究。 确定有和没有艾滋病毒感染的老年人的可改变的结果。我们也感到自豪的是 我们为年轻的研究人员提供教育、培训、职业发展和领导经验，其中许多 他们已经过渡到独立的国家卫生研究院和退伍军人事务部资助。我们持续的使命是建立和传播 优化对因酒精而遭受医疗伤害的艾滋病毒(PAH)老年患者的护理所需的证据 通过良好协调和充分整合的观察性和干预性研究。有权访问国家 EHR数据包括药物灌装/再灌装数据，我们在研究与以下相关的危害方面处于独特地位 同时使用酒精和多种药物(综合药房)。为了服务于我们更大的使命，我们的 方案项目申请支持创建艾滋病毒和酒精研究中心，重点是 多药联用(HARP)，以应对与有害酒精使用和多药联用相关的风险(AP风险)。这个 ADA核心由经验丰富的研究组成，分为行政和数据分析两个部分 协调员和扩大的数据管理、高性能计算、 生物统计学和人工智能。核心将解决清理和分析大型 规模、纵向EHR数据与其他数据源(例如，调查、生物标志物和遗传学)相结合，以 支持观察性和试验性干预研究。通过促进和通知数据访问、分析方法、 与我们更大的网络保持良好的通信线路，ADA核心将增强 HARP的意义和影响，提供没有的经验和资源是由项目资助的 分开的。凭借我们的经验、资源和势头，ADA核心处于独特的地位，可以满足 多环芳烃中的AP风险。

HARP ADA PROJECT SUMMARY Built on two decades of experience with large coordinated NIAAA-funded research projects on HIV and alcohol, The Veterans Aging Cohort Study (VACS) and our extended family of large, well characterized, national Veterans Healthcare Administration (VA) Cohorts (VACo Family) offer an unprecedented resource for the study of alcohol among people aging with and without HIV infection. Derived from Electronic Health Record (EHR), and subjected to rigorous data cleaning and phenotype validation, the VACo Family shares common data elements, including 20 years of longitudinal data on alcohol and health outcomes; it also includes behaviorally similar uninfected individuals, allowing us to characterize the role of HIV infection in determining alcohol associated outcomes; and supports targeted translational and intervention studies. To support excellence in the questions addressed, study design and analyses, we have cultivated an international collaborative network of experts. This well-established infrastructure has resulted in exceptional productivity. Our investigators have used data from the VACo Family to produce >500 peer reviewed publications, cited >26,000 times (h-index 79). We have successfully coordinated observational and intervention studies focused on the role of alcohol in determining modifiable outcomes among people aging with and without HIV infection. We are also proud of the education, training, career development, and leadership experience we offer young investigators, many of whom have transitioned to independent NIH and VA funding. Our ongoing mission is to build and disseminate the evidence needed to optimize care for people aging with HIV (PAH) experiencing medical harm from alcohol through well-coordinated and fully integrated observational and intervention studies. With access to national EHR data including medication fill/refill data, we are uniquely positioned to study harms associated with concurrent use of alcohol and multiple medications (polypharmacy). In service to our larger mission, our Program Project application supports the creation of the HIV and Alcohol Research center focused on Polypharmacy (HARP) to address risks associated with harmful alcohol use and polypharmacy (AP risk). The ADA Core, organized into administrative and data analytic sections, is composed of seasoned study coordinators and an expanded group of experts in data management, high performance computing, biostatistics, and artificial intelligence. The Core will address the challenges of cleaning and analyzing large scale, longitudinal EHR data combined with other data sources (e.g., surveys, biomarkers, and genetics) to support observational and pilot intervention studies. By facilitating and informing data access, analytic approach, and maintaining excellent lines of communication with our larger network, the ADA Core will enhance the significance and impact of HARP, providing experience and resources not available were projects funded separately. With our experience, resources, and momentum, the ADA Core is uniquely positioned to address AP risk among PAH.